An observational study in Very Low Birth Weight Baby, Early Nutrition and the Preterm Infant and Nutritional Requirements, sponsored by The Hospital for Sick Children. Recruiting at 6 sites in 2 countries. Open to participants aged 1 Hour to 21 Days. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by The Hospital for Sick Children · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Early nutrition critically influences growth, neurodevelopment and morbidity among infants born of very low birth weight (VLBW), but current one-size-fits-all feeding regimes do not optimally support these vulnerable infants. There is increasing interest in "precision nutrition" approaches, but it is unclear which Human Milk (HM) components require personalized adjustment of doses. Previous efforts have focused on macronutrients, but HM also contains essential micronutrients as well as non-nutrient bioactive components that shape the gut microbiome. Further, it is unclear if or how parental factors (e.g. body mass index, diet) and infant factors (e.g. genetics, gut microbiota, sex, acuity) influence relationships between early nutrition and growth, neurodevelopment and morbidity. Understanding these complex relationships is paramount to developing effective personalized HM feeding strategies for VLBW infants. This is the overarching goal of the proposed Optimizing Nutrition and Milk (Opti-NuM) Project.
The Opti-NuM Project brings together two established research platforms with complementary expertise and resources: 1) the MaxiMoM Program* with its clinically embedded translational neonatal feeding trial network in Toronto (Dr. Deborah O'Connor, Dr. Sharon Unger) and 2) the International Milk Composition (IMiC) Consortium, a world-renowned multidisciplinary network of HM researchers and data scientists collaborating to understand how the myriad of HM components contribute "as a whole" to infant growth and development, using systems biology and machine learning approaches. Members of the IMiC Corsortium that will work with on this study are located at the University of Manitoba (Dr. Meghan Azad), University of California (Dr. Lars Bode) and Stanford (Dr. Nima Aghaeepour).
Observational study mode:
The Opti-NuM Project is a retrospective secondary data/sample use study.
Time perspective:
Secondary use data and biospecimens accruing from the 2 completed studies DoMINO and OptiMOM (NCT02137473) and 1 ongoing RCT MaxiMoM (NCT05308134) are included in this project.
Sampling method:
This project is a secondary use of data/samples, from a cohort consisting of participants of the MaxiMoM Platform RCTs.
185 studies on the registry are indexed under Birth Weight; 24 are open to participants now.
This study's planned enrollment of 1,100 is above the median of 240 across 63 observational studies indexed under Birth Weight.
Browse Birth Weight studies →The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Very Low Birth Weight infants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Secondary data use and biospecimens from participants of the MaxiMoM Platform Trials are infants born 1500g or less (infant weight), born in the Greater Toronto Area.
Other: Opti-NuM is an observational secondary use of data/samples study, the investigators will analyze information and specimens from the MaxiMoM platform RCTs. No interventions form part of this study.
Cognitive composite score on the Bayley Scales of Infant and Toddler Development.
Our primary outcome is the cognitive composite score on the Bayley Scales of Infant and Toddler Development collected from the medical record or by home-visit by our research staff. The Bayley is the most widely used instrument globally by clinicians and researchers to assess developmental functioning of infants, toddlers and young children across cognitive, language (receptive, expressive) and motor (fine, gross) domains. Cognitive, language and motor composite scores will be standardized to a mean of 100 with a standard deviation of 15. The range on the composite Bayle Scores is from less than 0.1 to more than 99.9 percentile. A score lower than the 10th percentile indicates developmental delay.
Time frame: At 18-24 months CA
Language composite score from the Bayley Scales of Infant and Toddler Development
Language composite score from the Bayley Scales of Infant and Toddler Development. The range on the composite Bayle Scores is from less than 0.1 to more than 99.9 percentile. A score lower than the 10th percentile indicates developmental delay.
Time frame: At 18-24 months CA
Motor composite score from the Bayley Scales of Infant and Toddler Development
Motor composite score from the Bayley Scales of Infant and Toddler Development. The range on the composite Bayle Scores is from less than 0.1 to more than 99.9 percentile. A score lower than the 10th percentile indicates developmental delay.
Time frame: At 18-24 months CA
Weight (g)
Weight gains serve as early indicators of the effectiveness of early nutrition and are on the causal pathway to neurodevelopment. Daily weights are prospectively extracted from medical records.
Time frame: Initial hospitalization, approximately 50 days; at 4 months and 18-24 months CA clinic visit.
Length (cm)
Length gains serve as early indicators of the effectiveness of early nutrition and are on the causal pathway to neurodevelopment. Weekly length is determined by research staff using length boards and standardized procedures.
Time frame: Initial hospitalization, approximately 50 days; at 4 months and 18-24 months CA clinic visit.
Head circumference (cm)
Head circumference (HC) gains serve as early indicators of the effectiveness of early nutrition and are on the causal pathway to neurodevelopment. Weekly HC measurements are determined by research staff using non-stretchable tape measures and standardized procedures.
Time frame: Initial hospitalization, approximately 50 days; at 4 months and 18-24 months CA clinic visit.
Serious morbidities
Serious morbidities including late-onset sepsis (\>day 5, positive blood or cerebrospinal fluid culture), NEC (Bell stage ≥II), chronic lung disease (respiratory support at 36 weeks) and retinopathy of prematurity requiring treatment are collected prospectively from the medical chart.
Time frame: During hospital stay, an average of 60 days.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — Data transfer will take place via Secure File Transfer Protocol (SFTP). Sub-agreements which cover data and sample sharing and confidentiality is in place.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: December 2024 to December 2027
Access criteria: During the Opti-NuM project the following institutions will be involved in data and sample analysis as indicated. Data sharing will take place through SFTP, bio specimens will be shipped for analyses. The Hospital for Sick Children (Lead, Deborah O'Connor PhD RD): Both data and sample analysis The University of Toronto (Lead, Deborah O'Connor PhD RD): Both data and sample analysis The University of Manitoba (Lead, Meghan Azad PhD): Data analysis; No sample analysis Stanford University (Lead, Nima Aghaeepour PhD): Data analysis; No sample analysis University of California (Lead, Lars Bode PhD): Oligosaccharide analysis of human milk samples only. No data provided to this site.
Started Oct 2010 (actual). Primary completion is estimated for Dec 2026, 194 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital for Sick Children →